Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Options Obesity-Fighting Technology from MD Anderson Cancer Center

Abstract:
Arrowhead Research Corporation (ARWR 1.11, -0.01, -0.89%) today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it.

Arrowhead Options Obesity-Fighting Technology from MD Anderson Cancer Center

Pasadena, CA | Posted on August 10th, 2010

The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas. Arrowhead sees the technology platform as an attractive candidate around which to form a new majority-owned subsidiary to steer the technology through clinical development.

"We've been tracking obesity and metabolic markets for some time and have been searching for technology with the potential of serving these markets in a unique and powerful way," said Christopher Anzalone, Arrowhead's CEO. "We believe the platform that Drs. Pasqualini and Arap have developed may represent a great leap forward in treating obesity, a condition with significant quality of life issues and virtually unparalleled direct and indirect economic costs. This is also a relatively advanced program from a development standpoint and could be ready to begin human clinical trials in the near term."

The breakthrough approach was first published in the prestigious scientific journal Nature Medicine in May 2004 and received widespread media attention, including write-ups in the Wall Street Journal and the New York Times. Since 2004, Drs. Pasqualini and Arap have worked to refine the technology and complete preclinical efficacy and toxicity testing in preparation for clinical trials.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (ARWR 1.11, -0.01, -0.89%) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its portfolio companies. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries, Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.

For more information, please click here

Contacts:
Investor Relations Contact:
The Piacente Group, Inc.
Brandi Floberg, 212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Academic/Education

Rice University launches Rice Synthetic Biology Institute to improve lives January 12th, 2024

Multi-institution, $4.6 million NSF grant to fund nanotechnology training September 9th, 2022

National Space Society Helps Fund Expanding Frontier’s Brownsville Summer Entrepreneur Academy: National Space Society and Club for the Future to Support Youth Development Program in South Texas June 24th, 2022

How a physicist aims to reduce the noise in quantum computing: NAU assistant professor Ryan Behunin received an NSF CAREER grant to study how to reduce the noise produced in the process of quantum computing, which will make it better and more practical April 1st, 2022

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Research partnerships

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

'Sudden death' of quantum fluctuations defies current theories of superconductivity: Study challenges the conventional wisdom of superconducting quantum transitions January 12th, 2024

Development of zinc oxide nanopagoda array photoelectrode: photoelectrochemical water-splitting hydrogen production January 12th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project